Broeks Annegien, Braaf Linde M, Huseinovic Angelina, Nooijen Anke, Urbanus Jos, Hogervorst Frans B L, Schmidt Marjanka K, Klijn Jan G M, Russell Nicola S, Van Leeuwen Flora E, Van 't Veer Laura J
Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Breast Cancer Res. 2007;9(2):R26. doi: 10.1186/bcr1668.
Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer.
We evaluated the contribution of germline mutations in the DDRP genes BRCA1, BRCA2, CHEK2 and ATM to the risk of radiation-induced contralateral breast cancer (CBC). The germline mutation frequency was assessed, in a case-only study, in women who developed a CBC after they had a first breast cancer diagnosed before the age of 50 years, and who were (n = 169) or were not (n = 78) treated with radiotherapy for their first breast tumour.
We identified 27 BRCA1, 5 BRCA2, 15 CHEK2 and 4 truncating ATM germline mutation carriers among all CBC patients tested (21%). The mutation frequency was 24.3% among CBC patients with a history of radiotherapy, and 12.8% among patients not irradiated for the first breast tumour (odds ratio 2.18 (95% confidence interval 1.03 to 4.62); p = 0.043). The association between DDRP germline mutation carriers and risk of radiation-induced CBC seemed to be strongest in women who developed their second primary breast tumour at least 5 years after radiotherapy. Those patients had an odds ratio of 2.51 (95% confidence interval 1.03 to 6.10; p = 0.049) of developing radiation-induced breast cancer, in comparison with non-carriers.
This study shows that carriers of germline mutations in a DDRP gene have an increased risk of developing (contralateral) breast cancer after radiotherapy; that is, over and above the risk associated with their carrier status. The increased risk indicates that knowledge of germline status of these DDRP genes at the time of breast cancer diagnosis may have important implications for the choice of treatment.
年轻时接受辐射是患乳腺癌的最强风险因素之一。参与DNA损伤修复途径(DDRP)的基因中的种系突变可能使女性更容易患辐射诱导的乳腺癌。
我们评估了DDRP基因BRCA1、BRCA2、CHEK2和ATM中的种系突变对辐射诱导的对侧乳腺癌(CBC)风险的影响。在一项仅涉及病例的研究中,对50岁之前首次诊断出患有乳腺癌且接受(n = 169)或未接受(n = 78)放疗治疗其首个乳腺肿瘤后发生对侧乳腺癌的女性进行种系突变频率评估。
在所有接受检测的CBC患者中(21%),我们鉴定出27名BRCA1、5名BRCA2、15名CHEK2和4名截短型ATM种系突变携带者。有放疗史的CBC患者中突变频率为24.3%,首个乳腺肿瘤未接受放疗的患者中突变频率为12.8%(优势比2.18(95%置信区间1.03至4.62);p = 0.043)。DDRP种系突变携带者与辐射诱导的CBC风险之间的关联在放疗后至少5年发生第二原发性乳腺肿瘤的女性中似乎最为强烈。与非携带者相比,这些患者发生辐射诱导乳腺癌的优势比为2.51(95%置信区间1.03至6.10;p = 0.049)。
本研究表明DDRP基因种系突变携带者在放疗后发生(对侧)乳腺癌的风险增加;也就是说,除了与其携带者状态相关的风险之外。风险增加表明,在乳腺癌诊断时了解这些DDRP基因的种系状态可能对治疗选择具有重要意义。